Literature DB >> 34797447

Risk Score Using Demographic and Clinical Risk Factors Predicts Gastric Intestinal Metaplasia Risk in a U.S. Population.

Mimi C Tan1, Quynh Ho2, Theresa H Nguyen3,4, Yan Liu3,4, Hashem B El-Serag3,4, Aaron P Thrift5,6.   

Abstract

BACKGROUND/AIMS: Screening for gastric intestinal metaplasia (GIM) may lead to early gastric cancer detection. We developed and validated a pre-endoscopy risk prediction model for detection of GIM based on patient-level risk factors in a U.S.
METHODS: We used data from 423 GIM cases and 1796 controls from a cross-sectional study among primary care and endoscopy clinic patients at the Houston VA. We developed the model using backwards stepwise regression and assessed discrimination using area under the receiver operating characteristic (AUROC). The model was internally validated using cross-validation and bootstrapping. The final expanded model was compared to a model including H. pylori infection alone and a baseline model including remaining terms without H. pylori.
RESULTS: Male sex, older age, non-white race/ethnicity, smoking status, and H. pylori were associated with GIM risk. The expanded model including these terms had AUROC 0.73 (95%CI 0.71-0.76) for predicting GIM and AUROC 0.82 (95%CI 0.79-0.86) for extensive GIM. This model discriminated better than a model including only H. pylori (AUROC 0.66; 95%CI 0.63-0.68) and the baseline model (AUROC 0.67; 95%CI 0.64-0.70). The expanded model performed similarly among primary care (AUROC 0.75) and endoscopy (AUROC 0.73) patients. The expanded model showed sufficient internal validity (cross-validation AUROC 0.72) with little evidence of over-fitting.
CONCLUSIONS: We develop and validate a non-invasive risk model for GIM detection in a U.S. population that included terms for sex, age, race/ethnicity, smoking status, and H. pylori infection. Validated risk models would identify individuals with GIM who should be referred for endoscopic screening.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Epidemiology; Gastric cancer; Gastric intestinal metaplasia; Helicobacter pylori; Risk prediction

Mesh:

Year:  2021        PMID: 34797447      PMCID: PMC9117573          DOI: 10.1007/s10620-021-07309-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  31 in total

1.  Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis.

Authors:  Zhensheng Wang; David Y Graham; Anam Khan; Maya Balakrishnan; Hannah R Abrams; Hashem B El-Serag; Aaron P Thrift
Journal:  Int J Epidemiol       Date:  2018-06-01       Impact factor: 7.196

2.  Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells.

Authors:  S Lorente; O Doiz; M Trinidad Serrano; J Castillo; A Lanas
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

3.  Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening.

Authors:  M Dinis-Ribeiro; G Yamaki; K Miki; A Costa-Pereira; M Matsukawa; M Kurihara
Journal:  J Med Screen       Date:  2004       Impact factor: 2.136

Review 4.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

Authors:  M F Dixon; R M Genta; J H Yardley; P Correa
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

Review 5.  Screening and surveillance for gastric cancer in the United States: Is it needed?

Authors:  Gwang Ha Kim; Peter S Liang; Sung Jo Bang; Joo Ha Hwang
Journal:  Gastrointest Endosc       Date:  2016-03-03       Impact factor: 9.427

6.  A model for gastric cancer epidemiology.

Authors:  P Correa; W Haenszel; C Cuello; S Tannenbaum; M Archer
Journal:  Lancet       Date:  1975-07-12       Impact factor: 79.321

7.  Results of initial low-dose computed tomographic screening for lung cancer.

Authors:  Timothy R Church; William C Black; Denise R Aberle; Christine D Berg; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; David S Gierada; Gordon C Jones; Irene Mahon; Pamela M Marcus; JoRean D Sicks; Amanda Jain; Sarah Baum
Journal:  N Engl J Med       Date:  2013-05-23       Impact factor: 91.245

8.  Demographic and Lifestyle Risk Factors for Gastric Intestinal Metaplasia Among US Veterans.

Authors:  Mimi C Tan; Niharika Mallepally; Yan Liu; Hashem B El-Serag; Aaron P Thrift
Journal:  Am J Gastroenterol       Date:  2020-03       Impact factor: 10.864

Review 9.  Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis.

Authors:  Ya-kai Huang; Jian-chun Yu; Wei-ming Kang; Zhi-qiang Ma; Xin Ye; Shu-bo Tian; Chao Yan
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

10.  Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients.

Authors:  Yifat Snir; Haim Leibovitzh; Yaara Leibovici-Weissman; Alex Vilkin; Arnon D Cohen; Tzippy Shochat; Yaron Niv; Iris Dotan; Ilan Feldhamer; Doron Boltin; Zohar Levi
Journal:  United European Gastroenterol J       Date:  2021-03-18       Impact factor: 4.623

View more
  2 in total

1.  Impact of Comorbid Psychiatric Disorders on Healthcare Utilization in Patients with Inflammatory Bowel Disease: A Nationally Representative Cohort Study.

Authors:  Eddie Hill; Nghia H Nguyen; Alexander S Qian; Sagar Patel; Peter L Chen; Chung-Sang Tse; Siddharth Singh
Journal:  Dig Dis Sci       Date:  2022-05-03       Impact factor: 3.487

2.  Prevalence of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases.

Authors:  Karel Kostev; Sven Loosen; Christoph Roderburg
Journal:  Dig Dis Sci       Date:  2021-07-29       Impact factor: 3.487

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.